{
    "id": 934,
    "fullName": "RET C634R",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "RET C634R lies within the extracellular domain of the Ret protein (UniProt.org). C634R results in autophosphorylation of Ret, and is transforming in cultured cells (PMID: 9242375, PMID: 10679286).",
            "references": [
                {
                    "id": 432,
                    "pubMedId": 9242375,
                    "title": "Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/9242375"
                },
                {
                    "id": 11578,
                    "pubMedId": 10679286,
                    "title": "A two-hit model for development of multiple endocrine neoplasia type 2B by RET mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/10679286"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 5979,
        "geneSymbol": "RET",
        "terms": [
            "RET",
            "CDHF12",
            "CDHR16",
            "HSCR1",
            "MEN2A",
            "MEN2B",
            "MTC1",
            "PTC",
            "RET-ELE1"
        ]
    },
    "variant": "C634R",
    "createDate": "07/11/2014",
    "updateDate": "10/16/2018",
    "referenceTranscriptCoordinates": {
        "id": 125233,
        "transcript": "NM_020975",
        "gDna": "chr10:g.43114500T>C",
        "cDna": "c.1900T>C",
        "protein": "p.C634R",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 6188,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pz-1 inhibited Ret signaling in transformed cells over expressing RET C634R and inhibited tumor growth in cell line xenografts models (PMID: 26126987).",
            "molecularProfile": {
                "id": 2945,
                "profileName": "RET C634R"
            },
            "therapy": {
                "id": 4089,
                "therapyName": "Pz-1",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5385,
                    "pubMedId": 26126987,
                    "title": "Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26126987"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1850,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed human cell lines expressing RET C634R demonstrated sensitivity to Iclusig (ponatinib) (PMID: 23811235).",
            "molecularProfile": {
                "id": 2945,
                "profileName": "RET C634R"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 602,
                    "pubMedId": 23811235,
                    "title": "Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23811235"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10452,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Nexavar (sorafenib) treatment resulted in partial response in 50% (1/2) and stable disease in 50% (1/2) of patients with medullary thyroid carcinoma harboring RET C634R (PMID: 20368568).",
            "molecularProfile": {
                "id": 2945,
                "profileName": "RET C634R"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3973,
                "name": "thyroid gland medullary carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8463,
                    "pubMedId": 20368568,
                    "title": "Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20368568"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 2190,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nexavar (sorafenib) inhibited RET kinase activity and proliferation in transformed cells expressing RET C634R in culture (PMID: 16507829).",
            "molecularProfile": {
                "id": 2945,
                "profileName": "RET C634R"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2736,
                    "pubMedId": 16507829,
                    "title": "BAY 43-9006 inhibition of oncogenic RET mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16507829"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1765,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nexavar (sorafenib) inhibited RET phosphorylation and decreased growth of cells expressing RET C634R in culture (PMID: 17664273).",
            "molecularProfile": {
                "id": 2945,
                "profileName": "RET C634R"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 589,
                    "pubMedId": 17664273,
                    "title": "Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17664273"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3423,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Caprelsa (vandetanib) inhibited RET phosphorylation and decreased growth of transformed cells expressing RET C634R in culture (PMID: 15184865).",
            "molecularProfile": {
                "id": 2945,
                "profileName": "RET C634R"
            },
            "therapy": {
                "id": 953,
                "therapyName": "Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3687,
                    "pubMedId": 15184865,
                    "title": "Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15184865"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3468,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cell lines expressing Ret protein carrying both C634R and V804G mutations were more sensitive to Vandetanib induced inhibition of Ret activity than cells expressing Ret C634R alone in culture (PMID: 15184865).",
            "molecularProfile": {
                "id": 13345,
                "profileName": "RET C634R RET V804G"
            },
            "therapy": {
                "id": 953,
                "therapyName": "Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3687,
                    "pubMedId": 15184865,
                    "title": "Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15184865"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10660,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed human cells co-expressing RET C634R and RET V804M were resistant to treatment with Caprelsa (vandetanib) in culture (PMID: 19029224).",
            "molecularProfile": {
                "id": 27716,
                "profileName": "RET C634R RET V804M"
            },
            "therapy": {
                "id": 953,
                "therapyName": "Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 8446,
                    "pubMedId": 19029224,
                    "title": "Identification of tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19029224"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10661,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed human cells co-expressing RET C634R and RET Y806C were resistant to treatment with Caprelsa (vandetanib) in culture (PMID: 19029224).",
            "molecularProfile": {
                "id": 27717,
                "profileName": "RET C634R RET Y806C"
            },
            "therapy": {
                "id": 953,
                "therapyName": "Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 8446,
                    "pubMedId": 19029224,
                    "title": "Identification of tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19029224"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10662,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed human cells co-expressing RET C634R and RET Y806E were resistant to treatment with Caprelsa (vandetanib) in culture (PMID: 19029224).",
            "molecularProfile": {
                "id": 27718,
                "profileName": "RET C634R RET Y806E"
            },
            "therapy": {
                "id": 953,
                "therapyName": "Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 8446,
                    "pubMedId": 19029224,
                    "title": "Identification of tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19029224"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10663,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed human cells co-expressing RET C634R and RET Y806F in culture demonstrated inhibition of Ret phosphorylation and activity in kinase assays when treated with Caprelsa (vandetanib) (PMID: 19029224).",
            "molecularProfile": {
                "id": 27719,
                "profileName": "RET C634R RET Y806F"
            },
            "therapy": {
                "id": 953,
                "therapyName": "Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8446,
                    "pubMedId": 19029224,
                    "title": "Identification of tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19029224"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 2945,
            "profileName": "RET C634R",
            "profileTreatmentApproaches": [
                {
                    "id": 380,
                    "name": "RET Inhibitor",
                    "profileName": "RET C634R"
                }
            ]
        },
        {
            "id": 13345,
            "profileName": "RET C634R RET V804G",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27716,
            "profileName": "RET C634R RET V804M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27717,
            "profileName": "RET C634R RET Y806C",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27718,
            "profileName": "RET C634R RET Y806E",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27719,
            "profileName": "RET C634R RET Y806F",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 125233,
            "transcript": "NM_020975",
            "gDna": "chr10:g.43114500T>C",
            "cDna": "c.1900T>C",
            "protein": "p.C634R",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 125234,
            "transcript": "NM_020630",
            "gDna": "chr10:g.43114500T>C",
            "cDna": "c.1900T>C",
            "protein": "p.C634R",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}